Huang H, Wang T, Li W, Wu Z, et al. Safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer (SEGNO): study protocol for an open-label prospective phase II umbrella clinical trial. BMC Cancer 2025;25:432.
PMID: 40065286